The role of biological response modifiers in metastatic renal cell carcinoma.
Muss
H B
HB
Cancer Center of Wake Forest University, Department of Medicine, Bowman-Gray School of Medicine, Winston-Salem, NC 27103.
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007372:Interferons / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*
D000970:Antineoplastic Agents; D007376:Interleukin-2; D007372:Interferons